Tamoxifen and ERα36: Fertilizing the seeds of breast cancer metastasis
Hormonal therapies including tamoxifen have been a mainstay for the treatment of breast tumors that express the classical estrogen receptor ERa66. Wang et al. now report that tamoxifen may paradoxically stimulate ALDH-expressing breast cancer stem cells via activation of the ERa66 variant ERa36.One of the greatest advances in breast cancer therapy has been the stratification of tumors into subtypes based on expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. Tumors that express ER, known as ER-positive breast cancers, are the most common subtype of breast cancer, accounting for~70% of early-stage breast cancer diagnoses. They are highly curable, with 20-year disease-free survival rates approaching 80% for earliest stage tumors.
28
2018-08-29(万方平台首次上网日期,不代表论文的发表时间)
共2页
391-392